Please assess the completion status of the following clinical trial:

Trial Title: DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age~2. Undergoing a cardiac surgical procedure (i.e. isolated coronary artery bypass graft (CABG), isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy~3. Provide written informed consent~Exclusion Criteria:~1. Allergy to tranexamic acid~2. Undergoing minimally invasive surgery~3. Fulfill any of the following transfusion risk factors (A-D):~   A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or hemorrhagic disease D. Infective endocarditis (active)~4. History of previous cardiac surgery~5. Estimated glomerular filtration rate \<30 mL/min (CKD-EPI equation) or on dialysis~6. Pre-operative hemoglobin \> 170 g/L or \<110 g/L~7. Pre-operative thrombocytopenia (\<50,000 platelets per µL)~8. Expected circulatory arrest~9. Pregnancy or breast feeding~10. Previously enrolled in the DEPOSITION trial~11. Refusal of blood products~12. Pericardiectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Tranexamic Acid/Placebo (Type: ACTIVE_COMPARATOR): Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
- Intravenous Tranexamic Acid/Placebo (Type: ACTIVE_COMPARATOR): Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).